Doing more harm than good? Do systematic reviews of PET by health technology assessment agencies provide an appraisal of the evidence that is closer to the truth than the primary data supporting its use?

Journal of Nuclear Medicine

Volumn 52, Issue SUPPL. 2, 2011, Pages

  Ware, Robert E ^a   Hicks, Rodney J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cost effectiveness; Evidence based medicine; Health technology assessment; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; EVIDENCE BASED MEDICINE; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAL ASSESSMENT; MEDICAL SOCIETY; MOLECULAR IMAGING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC ERROR; SYSTEMATIC REVIEW (TOPIC); THORACOTOMY;

BIOMEDICAL TECHNOLOGY; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; HUMANS; INTERNATIONAL AGENCIES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC;

EID: 83755220913     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.086611     Document Type: Review

References (39)

1. Adams EJ, Almazan C, Morland B, Bradbury I, King R, Rheinberger P. Joint project of the International Network of Agencies for Health Technology Assessment: part 2 - managing the diffusion of positron emission tomography with health technology assessment. Int J Technol Assess Health Care. 2006;22:149-154.
2. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(suppl):1S- 93S. (Pubitemid 32423895)
3. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007;48(suppl 1):78S-88S. (Pubitemid 47604945)
4. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
5. Shankar LK, Sullivan DC. PET/CT in cancer patient management. J Nucl Med. 2007;48(suppl 1):1S.
6. Leeder SR, Rychetnik L. Ethics and evidence-based medicine. Med J Aust. 2001;175:161-164. (Pubitemid 32755192)
7. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138:W1-W12.
8. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
9. Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. JAMA. 1994;272:1367-1371. (Pubitemid 24323620)
10. Ware RE, Francis HW, Read KE. The Australian government's review of positron emission tomography: evidence-based policy-making in action. Med J Aust. 2004;180:627-632. (Pubitemid 38877946)
11. Hicks RJ. Editorial: health technology assessment and cancer imaging - who should be setting the agenda? Cancer Imaging. 2004;4:58.
12. Coleman RE, Hillner BE, Shields AF, et al. PET and PET/CT reports: observations from the National Oncologic PET Registry. J Nucl Med. 2010;51:158-163.
13. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261. (Pubitemid 30490393)
14. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803-809. (Pubitemid 29410986)
15. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg. 1999;67:790-797. (Pubitemid 29207699)
16. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck. 2005;27:175-181. (Pubitemid 40315765)
17. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. Dec 1995;60:1573-1581. (Pubitemid 26078244)
18. Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1994;271:389-391.
19. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604.
20. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med. 2001;42:1605-1613.
21. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492-499.
22. Mac Manus MP, Wong K, Hicks RJ, Matthews JP, Wirth A, Ball DL. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys. 2002;52:351-361. (Pubitemid 34170842)
23. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004;22:2357-2362. (Pubitemid 41115392)
24. Kalff V, Hicks R, Ware R, Binns D, McKenzie A. F-18 FDG PET for suspected or confirmed regional recurrence of colon cancer: a prospective study of impact and outcome. Clin Positron Imaging. 2000;3:183.
25. Scott AM, Gunawardana DH, Kelley B, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1451-1457.
26. Jackson T, Hicks RJ, MacManus MP. A Cost Consequence Study of Care Following Cancer Staging With and Without the Use of F-18 FDG PET Scanning: Final Report to the Consultative Committee on Diagnostic Imaging. Woden, Australia: Department of Health and Ageing; 2003.
27. 18F- Fluorodeoxyglucose positron emission tomography in restaging of colorectal cancer [in German]. Nuklearmedizin. 2003;42:145-156.
28. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-Analyses. Lancet. 1999;354:1896-1900.
29. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475-481.
30. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006;17:1296-1300. (Pubitemid 44288221)
31. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1393.
32. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. Clin Med. 2001;1:478-484.
33. Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med. 2006;144:850-855. (Pubitemid 46780618)
34. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926. (Pubitemid 351632017)
35. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88-94.
36. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312:71-72.
37. Muir-Gray JA. Evidence-Based Healthcare. Philadelphia, PA: Churchill Livingstone; 2001.
38. Kristensen FB, Adams E, Briones E, et al. Health technology assessment of PET in oncology. Eur J Nucl Med Mol Imaging. 2004;31:295-297.
39. Reitsma JB, Rutjes AWS, Whiting P, Vlassov VV, Leeflang MMG, Deeks JJ. Assessing methodologic quality. In: Deeks JJ, Bossuyt PM, Gatsonis C, eds Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy, Version 1.0.0. Available at: http://srdta.cochrane.org/sites/srdta.cochrane.org/files/ uploads/ch09-Oct09.pdf. Accessed November 3, 2011.